Trial Profile
The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Denosumab (Primary) ; Teriparatide (Primary)
- Indications Osteoporosis
- Focus Therapeutic Use
- 06 Nov 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 02 Jul 2014 New trial record